131 completed, 31 recruiting, 25 terminated, 20 active not recruiting. 88 Phase 2, 68 Phase 1, 31 Phase 3, 22 Not applicable, 3 Phase 4.
Follow Thrombocythemia, Essential: new trials by email Literature Review of Thrombocythemia, Essential trials Research Report on Thrombocythemia, Essential
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| WELL-MPN: A Digital Lifestyle App for Patients With MPNs WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs) | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 75 | 2027-01-01 | 2026-09-29 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-10-30 |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. - Myeloproliferative Disease, Polycythemia Vera | Not applicable | Not yet recruiting | Carmen Fava | 25 | 2026-08-01 | 2026-04-09 |
| CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA) VerifyNow P2Y12 assay - Essential Thrombocythemia | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 50 | 2026-07-15 | 2026-06-12 | |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-10-30 |
| Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm Myeloproliferative Neoplasm (MPN), Polycytemia Vera | Recruiting | Université Catholique de Louvain | 150 | 2026-05-01 | 2026-05-15 | |
| Safety and Tolerability of ZE74-0282 in Healthy Volunteers ZE74-0282-0001 or placebo - Healthy Volunteers | Phase 1 | Recruiting | Eilean Therapeutics AU Pty Ltd | 64 | 2026-04-16 | 2026-07-28 |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms INCA035784 - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 120 | 2025-10-01 | 2026-08-06 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-10-27 |
| A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial STP938 - Essential Thrombocythaemia | Phase 2 | Recruiting | Step Pharma, SAS | 50 | 2025-06-18 | 2026-06-16 |
| Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History NGS testing, NGS analysis for mutations in genes involved in familial predisposition to hematological malignancies - Polycythemia Vera, Essential Thrombocythaemia | Not applicable | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 496 | 2025-05-21 | 2025-05-15 |
| MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms Myelofibrosis (MF), Polycythemia Vera | Recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1190 | 2025-02-17 | 2026-10-07 | |
| Efficacy and Safety of Peginterferon in ET and PV. Peginterferon α-2b injection - Essential Thrombocythemia, Polycythemia Vera | Not applicable | Recruiting | Zhenya Hong | 40 | 2024-11-20 | 2024-12-16 |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis JBI-802 - Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) | Phase 1 / Phase 2 | Recruiting | Jubilant Therapeutics Inc. | 30 | 2024-10-21 | 2026-06-03 |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 54 | 2024-10-02 | 2025-12-17 |
| Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET Peginterferon α-2b injection - Essential Thrombocythemia | Phase 2 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 27 | 2024-08-29 | 2025-11-17 |
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Bomedemstat, Hydroxyurea, Bomedemstat placebo - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2024-07-16 | 2026-08-27 |
| Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes Monocytes signatures in myeloproliferative neoplasms at diagnosis - Myeloproliferative Neoplasm, Polycythemia Vera | Not applicable | Recruiting | University Hospital, Angers | 70 | 2024-05-29 | 2026-10-29 |
Showing 20 of 229. Sign in to see all of them.
Polycythemia Vera (174) · Primary Myelofibrosis (170) · Myeloproliferative Disorders (143) · Leukemia, Myeloid, Acute (85) · Leukemia, Myelomonocytic, Chronic (83) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (79) · Leukemia, Lymphocytic, Chronic, B-Cell (76) · Myelodysplastic Syndromes (73) · Multiple Myeloma (71) · Leukemia (68) · Lymphoma, Follicular (67) · Lymphoma, Large B-Cell, Diffuse (66) · Lymphoma, Mantle-Cell (66) · Burkitt Lymphoma (65)
Hemic and Lymphatic Diseases (229) · Blood Coagulation Disorders (226) · Blood Platelet Disorders (226) · Hemorrhagic Disorders (225) · Bone Marrow Diseases (221) · Hematologic Diseases (220) · Thrombocytosis (220) · Neoplasms by Site (177) · Bone Marrow Neoplasms (173) · Hematologic Neoplasms (170) · Neoplasms (167) · Pathological Conditions, Signs and Symptoms (108) · Neoplasms by Histologic Type (107) · Pathologic Processes (106) · Leukemia, Myeloid (105)
fludarabine phosphate (25) · Cyclophosphamide (24) · Peripheral Blood Stem Cell Transplantation (23) · Busulfan (18) · ruxolitinib (16) · Tacrolimus (15) · Cyclosporine (13) · Methotrexate (13) · Mycophenolic Acid (12) · Whole-Body Irradiation (12) · Antilymphocyte Serum (11) · anagrelide (11) · Filgrastim (8) · Decitabine (7) · bomedemstat (7)
Fred Hutchinson Cancer Center (13) · National Cancer Institute (NCI) (13) · Incyte Corporation (8) · Shire (8) · M.D. Anderson Cancer Center (6) · Icahn School of Medicine at Mount Sinai (5) · Mayo Clinic (5) · AOP Orphan Pharmaceuticals AG (4) · City of Hope Medical Center (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Alliance for Clinical Trials in Oncology (3) · Case Comprehensive Cancer Center (3) · Eli Lilly and Company (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Italfarmaco (3)
United States (149) · Italy (38) · France (37) · United Kingdom (29) · Germany (28) · Canada (20) · Australia (18) · Belgium (14) · Spain (14) · China (11) · Japan (11) · Poland (10) · Denmark (9) · Hungary (9) · Netherlands (9)
John Mascarenhas, MD (4) · Ronald Hoffman, MD (4) · Ruben A. Mesa, MD (4) · Alessandro Rambaldi, MD (3) · Charles A. Linker, MD (2) · H. Joachim Deeg, MD (2) · Jacob H Grauslund, MD (2) · Jorge Cortes, MD (2) · Keith W Pratz (2) · Richard K. Burt, MD (2) · Rona S Weinberg, PhD (2)
PMID 29246923, PMID 32499241, PMID 33275766, PMID 40775758, PMID 11468154, PMID 15459300, PMID 15570084, PMID 17397698, PMID 18698002, PMID 19841031, PMID 20651074, PMID 22259028, PMID 22480131, PMID 22943924, PMID 23184668, PMID 23199894, PMID 23315161, PMID 23358983, PMID 24118452, PMID 24334294, PMID 24362550, PMID 24474568, PMID 24903629, PMID 25160063, PMID 25563429, PMID 25762180, PMID 25939704, PMID 26028965, PMID 26113113, PMID 26175532, PMID 26210442, PMID 26332546, PMID 26700120, PMID 26700123, PMID 26853648, PMID 27020837, PMID 27291777, PMID 27479177, PMID 28291640, PMID 28482711, PMID 28622623, PMID 28623609, PMID 28740456, PMID 28934680, PMID 29079600, PMID 29152412, PMID 29164292, PMID 29217781, PMID 29266414, PMID 29616837
P01CA108671 (6), P30CA015083 (5), 2023 (4), P30CA006973 (4), P01CA018029 (3), P30CA015704 (3), P30CA016086 (3), P30CA033572 (3), 2004 (2), 2018 (2), 2019 (2), P01CA015396 (2), P30CA068485 (2), P30CA072720 (2), U01CA062491 (2)